High-dose thiotepa with autologous bone marrow rescue in recurrent malignant oligodendroglioma: a case report.
High-dose thiotepa with autologous bone marrow rescue is a new and promising treatment modality in several kinds of solid tumors. We used this regimen in a pediatric patient who had the third recurrence of his malignant oligodendroglioma of brain that developed during '8 in 1' chemotherapy. We achieved complete response after a total dose of 1125 mg/m2 of intravenous thiotepa. Good penetration into the CNS renders thiotepa potentially useful for chemosensitive brain tumors, and one course of high-dose thiotepa can be administered with acceptable toxicity by utilizing autologous bone marrow rescue.
Saarinen
U M
UM
Children's Hospital, University of Helsinki, Finland.
Pihko
H
H
Mäkipernaa
A
A
D016026:Bone Marrow Transplantation; D001932:Brain Neoplasms / Q000188:drug therapy* / Q000601:surgery; D002648:Child; D003131:Combined Modality Therapy; D004305:Dose-Response Relationship, Drug; D006801:Humans; D008297:Male; D009364:Neoplasm Recurrence, Local; D009837:Oligodendroglioma / Q000188:drug therapy* / Q000601:surgery; D010865:Pilot Projects; D013852:Thiotepa / Q000008:administration & dosage / Q000627:therapeutic use*; D014182:Transplantation, Autologous
D013852:Thiotepa